Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis

Basic Details
Date Posted
Tuesday, June 14, 2022
Status
Complete
Medical Product
bamlanivimab
bamlanivimab etesevimab
casirivimab imdevimab
Health Outcome(s)
utilization
Description

In this report we estimated rates of monoclonal antibody (mAb) utilization, including bamlanivimab, casirivimab and/or imdevimab, and bamlanivimab and etesevimab, among authorized and unauthorized users, and examined counts of patients with Coronavirus Disease 2019 (COVID-19) in the Rapid COVID Sentinel Distributed Database (SDD).

  • Group 1: The study period includes data from November 1, 2020 to June 22, 2021. We distributed this request to three Sentinel Data Partners on August 2, 2021.
  • Group 2: The study period includes data from November 1, 2020 to June 30, 2021. We distributed this request to two Sentinel Data Partners on August 2, 2021.

 

Deliverables (2)
Sentinel Modular Program Report:Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis, Group 1 Sentinel Modular Program Report: Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis, Group 2
Additional Details
FDA Center
CDER
Time Period
November 1, 2020 - June 22, 2021; November 1, 2020 - June 30, 2021
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Senitnel Drug Analysis: Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis
Sentinel Drug Analysis: Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis
Scroll to Top